A new IMA review examines psychedelic-assisted therapies for treatment-resistant depression, highlighting clinical promise alongside safety considerations.
Depression affects hundreds of millions worldwide. And for many, standard antidepressants simply don’t work. In cases of treatment-resistant depression (TRD), a growing number of doctors are turning to psychedelic-assisted therapies as a possible way forward.
It’s a field that’s seen a quiet but growing resurgence. Mainstream podcasts have touched the surface. But stigma and legal roadblocks still hang over the conversation, slowing progress and clouding perception. What’s overhyped? What’s actually hopeful?
Researchers at the Independent Medical Alliance (IMA) set out to answer those questions. Led by Dr. Joseph Varon, Chief Medical Officer; Matthew Halma, Director of Scientific Research; and Rakeem Levy, the team published a new review in Brain Disorders that explores both the clinical promise and the risks of integrating psychedelics into mainstream care.
“Our hope is that this review will inform clinicians, policymakers, and the public about both the opportunities and the responsibilities inherent in this new therapeutic frontier. With careful stewardship, psychedelics could transform the landscape of mental health care.” — Halma, Levy, Varon
With great power comes great responsibility: Promise and caution in the new psychedelic renaissance – Authors: Matthew Halma, Rakeem Levy, Joseph Varon
What Does The Research Actually Say?
The review pulls from a mix of clinical trials, real-world studies, and recent policy shifts. These recent works are all centered on compounds like DMT, 5-MeO-DMT, ketamine, LSD, and psilocybin.
Ketamine stands out for its fast-acting effects in people with treatment-resistant depression, though the benefits often fade quickly. Psilocybin and ayahuasca have shown meaningful symptom relief in both lab and natural settings. MDMA and LSD-assisted psychotherapy are also showing promise, especially for mood-related disorders.
But there’s a catch: these therapies aren’t DIY. While researchers are rightly bringing attention to the benefits of psychedelics in some therapeutic contexts, it is important to emphasize nuance and avoid blanket recommendations. Fundamentally, psychedelics present a radically different model than what most practitioners are familiar with, and patients benefit from a greater dialogue between the medical mainstream and the psychedelic community, which have largely been separate.
Still, interest is clearly growing. Not just among patients, but in the scientific and policy communities too. That growing momentum, while no guarantee of access, is reshaping the conversation in a way that was unthinkable just a few years ago.
Evolving Legal and Policy Landscape
The policy landscape is shifting. The review points to a few big moments that show how quickly things are changing, not just in labs, but in law.
- Oregon legalized supervised psilocybin therapy in November 2020
- Colorado passed Proposition 122 in November 2022, allowing regulated therapeutic use
- Australia approved prescription psilocybin and MDMA for psychiatric treatment in February 2023
Together, these changes signal a major cultural and regulatory turning point. Once confined to underground or recreational spaces, psychedelics are now being cautiously reintroduced through legitimate medical channels.
And in the U.S., Secretary of Health and Human Services Robert F. Kennedy Jr. has voiced public support for advancing psychedelic treatments, especially for PTSD.
Though the data points to promise, we are still a long way from full access. And the authors are careful to note that these therapies aren’t right for everyone. There’s also the risk of self-treatment. What happens when people, encouraged by the science, try these substances without structure or oversight? It’s not hard to see how that opens the door to serious concerns around safety, screening, and consistency.
A History of Restrictions, A Future of Responsibility
For decades, psychedelics have been off-limits in most clinical settings. In 1970, drugs like LSD and psilocybin were labeled as Schedule I substances. That means they were considered to have no medical use and a high potential for abuse. That effectively shut the door on research. But even then, people didn’t stop using them. Some turned to underground treatments; others traveled abroad. The science, however, was largely stuck in place.
Now that laws are starting to shift and better data is emerging, researchers at IMA believe it’s time to take a closer look, exploring where they might responsibly fit into modern mental health care.
IMA’s Commitment to Evidence-Based Care
IMA’s research team is looking for gaps where medical science is failing to meet the needs of real patients. We started on this path during COVID, when outdated protocols left too many people behind. That same urgency now drives our work on mental health, cancer, and other areas where the standard of care is overdue for reinvention.
This latest study is part of that mission. It offers a grounded look at psychedelic therapies not as a miracle cure but as a set of tools worth investigating with rigor. This field is promising, but the authors are calling for deeper research into:
- Long-term safety
- Optimal dosing strategies
- Mechanisms of action
Since these compounds interact with different psychiatric conditions, there are many layers of consideration for patients and practitioners. The need for clinician education and structured training programs is real. The hope is that any future integration happens with clinical responsibility, not commercial haste. The road ahead is complex, but with the right questions—and the right safeguards—IMA believes responsible progress is possible.
For more of IMA’s recently published studies, check out the following:
- From Fringe to Focus: How Research Is Catching Up to Post-Acute COVID-19 Vaccination Syndrome (PACVS)
- Struggling with Chronic Pain? New Research Unveils Innovative Approaches to Pain and Opioid Use Disorder
- DARE-SAFE: A New Standard for Comparing Vaccine and Drug Safety
- Nature’s Overlooked Osteoporosis Solution: New Study Finds Up to 6% Bone Density Gains
- Feeling Anxious? New Study Shows Ashwagandha, CBD, and Saffron Effective for Anxiety Disorders
- New Peer-Reviewed Study Asks: Were COVID Injections Engineered to Harm?
